Marinus Pharmaceuticals Inc (MRNS) concluded trading on Thursday at a closing price of $0.32, with 2.69 million shares of worth about $0.86 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -73.76% during that period and on December 26, 2024 the price saw a gain of about 25.51%. Currently the company’s common shares owned by public are about 55.19M shares, out of which, 41.87M shares are available for trading.
Stock saw a price change of 32.51% in past 5 days and over the past one month there was a price change of -0.31%. Year-to-date (YTD), MRNS shares are showing a performance of -97.03% which decreased to -97.01% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.22 but also hit the highest price of $11.26 during that period. The average intraday trading volume for Marinus Pharmaceuticals Inc shares is 2.63 million. The stock is currently trading 15.73% above its 20-day simple moving average (SMA20), while that difference is down -32.89% for SMA50 and it goes to -83.81% lower than SMA200.
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) currently have 55.19M outstanding shares and institutions hold larger chunk of about 62.83% of that.
The stock has a current market capitalization of $17.81M and its 3Y-monthly beta is at 1.20. It has posted earnings per share of -$2.47 in the same period. It has Quick Ratio of 1.47. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRNS, volatility over the week remained 15.17% while standing at 9.13% over the month.
Stock’s fiscal year EPS is expected to rise by 22.86% while it is estimated to increase by 68.46% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on September 23, 2024 offering an Outperform rating for the stock and assigned a target price of $6 to it. On April 16, 2024, Robert W. Baird Downgrade their recommendations, while on April 15, 2024, RBC Capital Mkts Downgrade their ratings for the stock with a price target of $3. Stock get a Perform rating from Oppenheimer on August 11, 2023.
